Business Wire·Oct 9, 2026, 11:37 AM ET

bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. closed a registered direct offering of common stock & pre-funded warrants at prices of $6.122 & $6.115 respectively.
The company concurrently closed a private placement of warrants to purchase up to 980,072 shares at an exercise price of $6.122 per share.
Pre-funded warrants carry an exercise price of $0.007, while the common stock warrants are exercisable following stockholder approval & expire five years later.
WallachBeth Capital, LLC served as the sole placement agent for the transaction.
Gross proceeds from the offering totaled approximately $4 million before fees & expenses.
Net proceeds will be allocated to working capital, supporting sales of the CyPath® Lung test, & general corporate purposes.
The offering was executed under a shelf registration statement on Form S-3 declared effective by the SEC on November 27, 2023.
bioAffinity Technologies develops noninvasive healthcare solutions for early lung disease detection & markets CyPath® Lung as a Laboratory Developed Test.